Abstract:A hollow mesoporous silica nanoparticle (HMSNP) based drug/siRNA co-delivery system was designed and fabricated, aiming at overcoming multidrug resistance (MDR) in cancer cells for targeted cancer therapy. The as-prepared HMSNPs have perpendicular nanochannels connecting to the internal hollow cores, thereby facilitating drug loading and release. The extra volume of the hollow core enhances the drug loading capacity by two folds as compared with conventional mesoporous silica nanoparticles (MSNPs). Folic acid conjugated polyethyleneimine (PEI-FA) was coated on the HMSNP surfaces under neutral conditions through electrostatic interactions between the partially charged amino groups of PEI-FA and the phosphate groups on the HMSNP surfaces, blocking the mesopores and preventing the loaded drugs from leakage. Folic acid acts as the targeting ligand that enables the co-delivery system to selectively bind with and enter into the target cancer cells. PEI-FA-coated HMSNPs show enhanced siRNA binding capability on account of electrostatic interactions between the amino groups of PEI-FA and siRNA, as compared with that of MSNPs. The electrostatic interactions provide the feasibility of pH-controlled release. In vitro pH-responsive drug/siRNA co-delivery experiments were conducted on HeLa cell lines with high folic acid receptor expression and MCF-7 cell lines with low folic acid receptor expression for comparison, showing effective target delivery to the HeLa cells through folic acid receptor meditated cellular endocytosis. The pH-responsive intracellular drug/siRNA release greatly minimizes the prerelease and possible side effects of the delivery system. By simultaneously delivering both doxorubicin (Dox) and siRNA against the Bcl-2 protein into the HeLa cells, the expression of the anti-apoptotic protein Bcl-2 was successfully suppressed, leading to an enhanced therapeutic efficacy. Thus, the present multifunctional nanoparticles show promising potentials for controlled and targeted drug and gene co-delivery in cancer treatment.

Biomimetic, folic acid-modified mesoporous silica nanoparticles with “stealth” and “homing” capabilities for tumor therapy

Biomimetic Mesoporous Silica Nanoparticles for Enhanced Blood Circulation and Cancer Therapy.

Tlyp-1-conjugated Mesoporous Silica Nanoparticles for Tumor Targeting and Penetrating Hydrophobic Drug Delivery

Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.

Evaluating biological activity of folic acid-modified and 10-hydroxycamptothecin-loaded mesoporous silica nanoparticles

Biocompatible, uniform, and redispersible mesoporous silica nanoparticles for cancer-targeted drug delivery in vivo

Cloaking Mesoporous Silica Nanoparticles with Phenylboronic Acid-Conjugated Human Serum Albumin-Co-polydopamine Films for Targeted Drug Delivery

Engineering of Hollow Mesoporous Silica Nanoparticles for Remarkably Enhanced Tumor Active Targeting Efficacy

Hierarchical Integration of Degradable Mesoporous Silica Nanoreservoirs and Supramolecular Dendrimer Complex As a General-Purpose Tumor-Targeted Biomimetic Nanoplatform for Gene/small-Molecule Anticancer Drug Co-Delivery

Active stealth and self-positioning biomimetic vehicles achieved effective antitumor therapy

Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.

Dual Responsive Mesoporous Silica Nanoparticles for Targeted Co-Delivery of Hydrophobic and Hydrophilic Anticancer Drugs to Tumor Cells.

Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.

Anti-phagocytosis and tumor cell targeting micelles prepared from multifunctional cell membrane mimetic polymers

In situ phagocyte-mediated deep tumor penetration assisted by ApoA-1 mimetic peptide-modified silicasome

Stepwise-Acid-Active Multifunctional Mesoporous Silica Nanoparticles for Tumor-Specific Nucleus-Targeted Drug Delivery

Cancer cell membrane coated PLGA nanoparticles as biomimetic drug delivery system for improved cancer therapy

A Multifunctional Mesoporous Silica Nanocomposite for Targeted Delivery, Controlled Release of Doxorubicin and Bioimaging.

Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery to Potentiate the Antitumor Efficacy.

Novel biomimetic mesoporous silica nanoparticles system possessed targetability and immune synergy to promote solid tumor immuno- chemotherapy efficacy

Hyaluronic acid-modified mesoporous silica-coated superparamagnetic Fe 3 O 4 nanoparticles for targeted drug delivery.